Search

Eli Lilly and Co.

Chiusa

SettoreSettore sanitario

1,443.56 1.18

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1438.06

Massimo

1447.24

Metriche Chiave

By Trading Economics

Entrata

-644M

6.5B

Vendite

1.4B

24B

P/E

Media del settore

43.945

68.089

EPS

7.48

Rendimento da dividendi

0.49

Margine di Profitto

26.442

Dipendenti

50,000

EBITDA

-3.7B

9.3B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+4.84% upside

Dividendi

By Acuity

Rendimento da dividendi

Media del settore

0.49%

1.98%

Utili prossimi

3 feb 2027

Prossima data del Dividendo

10 dic 2026

Prossima data del' Ex Dividendo

12 feb 2027

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

118B

1.3T

Apertura precedente

1442.38

Chiusura precedente

1443.56

Eli Lilly and Co. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 nov 2026, 01:01 UTC

Eli Lilly and Company shares are declining in after-market trading, having pulled back from a brief peak shortly after the market closed.

13 nov 2026, 23:01 UTC

Eli Lilly and Company shares are modestly lower in after-market trading, reflecting a broadly declining market amid rising inflation concerns and Treasury yields.

12 nov 2026, 23:02 UTC

Eli Lilly and Company shares are trading lower in after-market hours, reflecting a slight decline since Thursday's close, despite strong one-month gains.

11 nov 2026, 23:03 UTC

News
Event

Eli Lilly reports positive results from the TOGETHER-PsA trial, showing Taltz and Zepbound's efficacy in treating psoriatic arthritis with weight-related comorbidities.

9 nov 2026, 21:04 UTC

Social Media
Event
News

Eli Lilly reports positive Phase 3 trial results for Foundayo, showing significant reductions in obstructive sleep apnea severity among adults with obesity or overweight.

7 nov 2026, 00:02 UTC

Event

Eli Lilly and Company announces agreement with Hims & Hers Health to expand access to medications Zepbound and Foundayo.

6 nov 2026, 23:02 UTC

Event

Eli Lilly announces agreement with Hims & Hers to enhance access to medications Zepbound and Foundayo, with shares trading roughly flat in after-market hours.

5 nov 2026, 23:03 UTC

Eli Lilly shares are trading modestly lower in after-market hours, reflecting a broader market decline amid significant drops in major semiconductor stocks.

4 nov 2026, 23:02 UTC

Eli Lilly and Company shares gained modestly in after-market trading, remaining near the upper end of their one-month range following fluctuating returns.

3 nov 2026, 23:01 UTC

Eli Lilly and Company shares are trading modestly lower in after-market hours, retreating from a brief peak earlier in the session.

2 nov 2026, 23:06 UTC

Eli Lilly and Company is experiencing a modest increase in after-market trading, gaining slightly since Monday's close and positioned above its 20-day moving average.

30 ott 2026, 23:01 UTC

Social Media
News

JP Morgan maintains Overweight rating on Eli Lilly and raises price target to $165, with shares trading modestly higher in after-market hours.

29 ott 2026, 23:03 UTC

Eli Lilly and Company shares advanced during after-market hours, reflecting a broader upward trend in the Pharmaceuticals sub-sector.

28 ott 2026, 23:02 UTC

Event
Social Media

Eli Lilly announces positive topline results from its Phase 3 trial comparing retatrutide to Ozempic in adults with type 2 diabetes.

27 ott 2026, 20:07 UTC

Social Media
News

Eli Lilly announces a fourth-quarter 2026 dividend of $1.73 per share and reports strong Q2 results with net income of $7.09 billion.

23 ott 2026, 20:02 UTC

Social Media
News
Correlated Moves

Eli Lilly and Co shares are declining, continuing a downward trend since Thursday's close, while the broader Pharmaceuticals sector is also lower.

22 ott 2026, 20:07 UTC

Correlated Moves
Social Media
News

Eli Lilly breaks ground on a $5 billion manufacturing facility in Virginia, expected to create 650 permanent jobs and support U.S. manufacturing initiatives.

21 ott 2026, 20:07 UTC

News
Correlated Moves

Leerink Partners raised Eli Lilly's price target to $1.32k, while RBC Capital set a target of $1.5k, but shares are declining in today's session.

20 ott 2026, 23:02 UTC

News

Eli Lilly named RBC Capital's preferred pharmaceutical stock with a $1.5K price target, despite shares declining modestly in after-market hours.

19 ott 2026, 23:06 UTC

Event

Eli Lilly announces positive Phase 3 SHINE-2 study results for Omvoh in pediatric ulcerative colitis, with 81% of participants achieving clinical response at Week 12.

17 ott 2026, 00:01 UTC

Eli Lilly and Co shares are lower in after-market hours, reflecting broader market declines amid stronger-than-expected inflation metrics and significant inflows in U.S. TIC Flows.

16 ott 2026, 23:06 UTC

Eli Lilly and Co shares are trading slightly lower in after-market hours, reflecting routine fluctuations amid a stable broader market context.

15 ott 2026, 23:11 UTC

Social Media
Event

Eli Lilly announces new data showing treatment goals achieved for ulcerative colitis and Crohn's disease patients with Omvoh after one year.

14 ott 2026, 23:42 UTC

Social Media

Eli Lilly and Co's shares are trading lower in after-market hours, reflecting a broader market decline amid rising Treasury yields and inflation concerns.

13 ott 2026, 20:02 UTC

News
Correlated Moves
Social Media

Eli Lilly announces a clinical trial collaboration with Prelude Therapeutics for a Phase 1 trial involving abemaciclib and imlunestrant, contributing to bearish sentiment.

12 ott 2026, 20:07 UTC

News
Event
Social Media

Eli Lilly gains support as RBC Capital reiterates Outperform rating with a $1.5K price target, following new data from the TOGETHER-PsO Phase 3b trial.

9 ott 2026, 20:07 UTC

Social Media
Event
News
Correlated Moves

Eli Lilly presents new data from its Phase 3b TOGETHER-PsO trial, showing significant biomarker changes with the combination of Taltz and Zepbound for psoriasis treatment.

8 ott 2026, 23:05 UTC

Eli Lilly and Co shares are trading lower in after-market hours, reflecting a decline since Thursday's close and fluctuating near the lower end of its recent range.

7 ott 2026, 23:06 UTC

Eli Lilly and Co is trading slightly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month trading range.

6 ott 2026, 20:07 UTC

Social Media
News
Event

Eli Lilly contributed to a $120 million Series B funding round for General Medicine, raising total funding to $152 million, amid positive market sentiment.

Confronto tra pari

Modifica del prezzo

Eli Lilly and Co. Previsione

Obiettivo di Prezzo

By TipRanks

4.84% in crescita

Previsioni per 12 mesi

Media 1,513.318 USD  4.84%

Alto 1,700 USD

Basso 940 USD

Basato su 24 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Eli Lilly and Co. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

24 ratings

22

Acquista

1

Mantieni

1

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
help-icon Live chat